Pancreatic neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:25 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Pancreatic neoplasm – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Tisotumab Vedotin, Pembrolizumab, and Platinum Drug Combination for Patients with Advanced or Metastatic Solid Tumors https://clinicaltrials.eu/trial/study-of-tisotumab-vedotin-pembrolizumab-and-platinum-drug-combination-for-patients-with-advanced-or-metastatic-solid-tumors/ Wed, 29 Apr 2026 14:57:05 +0000 https://clinicaltrials.eu/trial/study-of-tisotumab-vedotin-pembrolizumab-and-platinum-drug-combination-for-patients-with-advanced-or-metastatic-solid-tumors/ This clinical trial is focused on studying the effects of a treatment called tisotumab vedotin on patients with locally advanced or metastatic solid tumors. These are types of cancers that have spread from their original location to other parts of the body. The study aims to evaluate how well tisotumab vedotin works on its own and in combination with other treatments. In some parts of the study, tisotumab vedotin is combined with pembrolizumab, a medication that helps the immune system fight cancer, and a platinum agent, which is a type of chemotherapy drug.

The study is divided into several parts. In some parts, patients will receive tisotumab vedotin alone, while in others, it will be given alongside pembrolizumab or both pembrolizumab and a platinum agent like cisplatin or carboplatin. These medications are administered through an intravenous infusion, which means they are given directly into the bloodstream through a vein. The study will observe the effects of these treatments over time to understand their impact on the cancer and any side effects that may occur.

The purpose of this study is to assess the antitumor activity of tisotumab vedotin and its combinations in treating these advanced cancers. The study will monitor how the tumors respond to the treatment, how long it takes for a response to occur, and the overall survival of the patients. This information will help determine the effectiveness and safety of the treatment options being tested.

]]>